SWOG clinical trial number
SWOG-9208

Health Status and Quality of Life (QL) in Patients with Early Stage Hodgkin's Disease: A companion study to SWOG-9133, Ancillary

Closed
Phase
Published
Abbreviated Title
Quality of Life Companion study - Hodgkin's
Activated
04/15/1994
Closed
04/24/2000

Research committees

Lymphoma

Eligibility Criteria Expand/Collapse

Patients entered on SWOG-9133; Pts. able to read and understand English.

Publication Information Expand/Collapse

2017

Seven year follow-up for energy/vitality outcomes in early stage hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208

C Moinpour;J Unger;P Ganz;T Wang;A Kornblith;E Gaynor;MA Bowers;S Balcerzak;G Gatti Gunderson;Mark Kaminski;H Erba;O Press;RI Fisher Journal of Cancer Survivorship:Research and Practice, 2017 Feb;11(1):32-40; 2016 Jul 12 [Epub ahead of print]

PMid: PMID27405732 | PMC number: PMC5233644

2007

Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions

PA Ganz;CC Gotay Journal of Clinical Oncology 25(32):5063-9

PMid: PMID17991922

2004

Predictors of vitality (energy/fatigue) in early stage hodgkin's disease (HD): results from Southwest Oncology Group (SWOG) study 9133

PA Ganz;CM Moinpour;S McCoy;DK Pauler;OW Press;RI Fisher Proc of the American Society of Clinical Oncology 23:567 (#6546)

2003

Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group study 9133

PA Ganz;CM Moinpour;DK Pauler;AB Kornblith;ER Gaynor;SP Balcerzak;GS Gatti;HP Erba;S McCoy;OW Press;RI Fisher Journal of Clinical Oncology 21(18):3512-3519

2000

Behavioral science research in the cooperative group setting: the Southwest Oncology Group Experience

CC Gotay;CM Moinpour;S Moody-Thomas;ER Gritz;KS Albain;E DeAntoni;L Hansen;PA Ganz Journal of the National Cancer Institute 92(17):1381-1387

Other Clinical Trials

SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
15%
Open
Phase